These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25568666)

  • 1. DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells.
    Yang Y; Bardeleben C; Frost P; Hoang B; Shi Y; Finn R; Gera J; Lichtenstein A
    Genes Cancer; 2014 Nov; 5(11-12):407-19. PubMed ID: 25568666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.
    Shi Y; Daniels-Wells TR; Frost P; Lee J; Finn RS; Bardeleben C; Penichet ML; Jung ME; Gera J; Lichtenstein A
    Cancer Res; 2016 Oct; 76(19):5822-5831. PubMed ID: 27530328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
    Zhang HR; Chen JM; Zeng ZY; Que WZ
    J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro.
    Zhang H; Chen J; Zeng Z; Que W; Zhou L
    Int J Mol Med; 2013 May; 31(5):1127-34. PubMed ID: 23503641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase.
    Srinivas KP; Viji R; Dan VM; Sajitha IS; Prakash R; Rahul PV; Santhoshkumar TR; Lakshmi S; Pillai MR
    Oncotarget; 2016 Apr; 7(17):24154-71. PubMed ID: 26992219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity.
    Vega MI; Shi Y; Frost P; Huerta-Yepez S; Antonio-Andres G; Hernandez-Pando R; Lee J; Jung ME; Gera JF; Lichtenstein A
    Mol Cancer Ther; 2019 Oct; 18(10):1822-1831. PubMed ID: 31395691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma.
    Quwaider D; Corchete LA; Misiewicz-Krzeminska I; Sarasquete ME; Pérez JJ; Krzeminski P; Puig N; Mateos MV; García-Sanz R; Herrero AB; Gutiérrez NC
    J Hematol Oncol; 2017 Apr; 10(1):92. PubMed ID: 28420429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of DEPTOR inhibits the proliferation, migration, and survival of osteosarcoma through PI3K/Akt/mTOR pathway.
    Hu B; Lv X; Gao F; Chen S; Wang S; Qing X; Liu J; Wang B; Shao Z
    Onco Targets Ther; 2017; 10():4379-4391. PubMed ID: 28932123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Turnover of the mTOR inhibitor, DEPTOR, and downstream AKT phosphorylation in multiple myeloma cells, is dependent on ERK1-mediated phosphorylation.
    Vega M; Chen Y; Shi Y; Gera J; Lichtenstein A
    J Biol Chem; 2022 Apr; 298(4):101750. PubMed ID: 35216969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells.
    Catena V; Bruno T; De Nicola F; Goeman F; Pallocca M; Iezzi S; Sorino C; Cigliana G; Floridi A; Blandino G; Fanciulli M
    Oncotarget; 2016 Oct; 7(43):70546-70558. PubMed ID: 27655709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.
    Wang Q; Zhou Y; Rychahou P; Harris JW; Zaytseva YY; Liu J; Wang C; Weiss HL; Liu C; Lee EY; Evers BM
    Cancer Res; 2018 Jun; 78(12):3163-3175. PubMed ID: 29666061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways.
    Wang Y; Xu W; Yan Z; Zhao W; Mi J; Li J; Yan H
    J Exp Clin Cancer Res; 2018 Mar; 37(1):63. PubMed ID: 29554968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DEPTOR suppresses the progression of esophageal squamous cell carcinoma and predicts poor prognosis.
    Ji YM; Zhou XF; Zhang J; Zheng X; Li SB; Wei ZQ; Liu T; Cheng DL; Liu P; Song K; Tan T; Zhu H; Guo JL
    Oncotarget; 2016 Mar; 7(12):14188-98. PubMed ID: 26893358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribosomal protein S27-like regulates autophagy via the β-TrCP-DEPTOR-mTORC1 axis.
    Xiong X; Liu X; Li H; He H; Sun Y; Zhao Y
    Cell Death Dis; 2018 Nov; 9(11):1131. PubMed ID: 30425236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DEPTOR is a direct NOTCH1 target that promotes cell proliferation and survival in T-cell leukemia.
    Hu Y; Su H; Liu C; Wang Z; Huang L; Wang Q; Liu S; Chen S; Zhou J; Li P; Chen Z; Liu H; Qing G
    Oncogene; 2017 Feb; 36(8):1038-1047. PubMed ID: 27593934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akt2 causes TGFβ-induced deptor downregulation facilitating mTOR to drive podocyte hypertrophy and matrix protein expression.
    Das F; Ghosh-Choudhury N; Lee DY; Gorin Y; Kasinath BS; Choudhury GG
    PLoS One; 2018; 13(11):e0207285. PubMed ID: 30444896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DEPTOR induces a partial epithelial-to-mesenchymal transition and metastasis via autocrine TGFβ1 signaling and is associated with poor prognosis in hepatocellular carcinoma.
    Chen J; Zhu H; Liu Q; Ning D; Zhang Z; Zhang L; Mo J; Du P; Liu X; Song S; Fan Y; Liang H; Liu J; Zhang B; Chen X
    J Exp Clin Cancer Res; 2019 Jun; 38(1):273. PubMed ID: 31228948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-treatment With Everolimus, an mTOR-Specific Antagonist, or Downregulation of ELK1 Enhances the Sensitivity of Pancreatic Cancer Cells to Genistein.
    Li T; Kuang T; Yang Z; Zhang Q; Zhang W; Fan Y
    Front Cell Dev Biol; 2021; 9():633035. PubMed ID: 34540820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIF-mediated Suppression of DEPTOR Confers Resistance to mTOR Kinase Inhibition in Renal Cancer.
    Doan H; Parsons A; Devkumar S; Selvarajah J; Miralles F; Carroll VA
    iScience; 2019 Nov; 21():509-520. PubMed ID: 31710966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.